Key Points
- Insider sale: David Krempa sold 4,166 Eton Pharmaceuticals shares for approximately $229,422, reducing his direct ownership by 8.76% to 43,381 shares. He had also sold 25,000 shares in August.
- Recent performance: Eton reported quarterly earnings of $0.43 per share, surpassing the $0.19 analyst estimate, while revenue of $37.59 million exceeded the $27.11 million consensus forecast.
- Analyst outlook: The stock has a “Moderate Buy” consensus rating from analysts, with an average price target of $67.50 versus its reported opening price of $54.77.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 4,166 shares of the business's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $55.07, for a total value of $229,421.62. Following the sale, the insider directly owned 43,381 shares of the company's stock, valued at $2,388,991.67. This represents a 8.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
David Krempa also recently made the following trade(s):
- On Monday, August 24th, David Krempa sold 25,000 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00.
Eton Pharmaceuticals Stock Down 1.5%
Shares of NASDAQ ETON opened at $54.77 on Wednesday. Eton Pharmaceuticals, Inc. has a 1 year low of $14.27 and a 1 year high of $66.37. The firm's 50-day moving average is $55.36 and its 200-day moving average is $39.57. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $1.57 billion, a PE ratio of 144.13 and a beta of 0.90.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The business had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. Equities analysts expect that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current year.
Hedge Funds Weigh In On Eton Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in ETON. Squarepoint Ops LLC bought a new stake in shares of Eton Pharmaceuticals in the second quarter worth about $2,156,000. HighTower Advisors LLC lifted its holdings in shares of Eton Pharmaceuticals by 187.2% during the 2nd quarter. HighTower Advisors LLC now owns 52,907 shares of the company's stock valued at $1,915,000 after purchasing an additional 34,484 shares in the last quarter. Sigma Planning Corp bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $1,086,000. Toth Financial Advisory Corp acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at approximately $43,000. Finally, Navellier & Associates Inc. acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at approximately $652,000. 27.86% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
ETON has been the subject of several recent research reports. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a research report on Tuesday, September 22nd. Wall Street Zen upgraded Eton Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 13th. Craig Hallum lifted their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, July 28th. B. Riley Financial reiterated a "buy" rating and issued a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Finally, Zacks Research raised Eton Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Monday, August 24th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $67.50.
View Our Latest Stock Analysis on Eton Pharmaceuticals
Eton Pharmaceuticals Company Profile
(
Get Free Report)
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company's strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.
Eton's portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
